A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from ...

Fintel reports that on November 3, 2025, UBS maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 69.00% Upside As of October 30, 2025, the average ...

Truist lowered the firm’s price target on DexCom (DXCM) to $82 from $94 and keeps a Buy rating on the shares. The company’s Q3 earnings and ...

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

The research note pointed out that DexCom shares have recently declined despite the upcoming 15-day product cycle and revenue growth that should align more closely with the company’s healthy volume ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Dexcom (Nasdaq:DXCM) shares took a hit after hours today on third-quarter results that came in ahead of the consensus ...